Abstract: Serious drug–drug interactions have led to the necessity of a drug manufacturer to withdraw or limit the use of marketed drugs. Screening for drug–drug interaction in early phases of drug development allows the avoidance of the development of drug candidates with high potential for adverse drug interactions. This article focuses on the scientific principles, technologies, and experimental approaches for the preclinical evaluation of drug–drug interactions. Keywords: drug–drug interactions; preclinical evaluation; screening; drug metabol...
(read more)
Topics: 
Pharmacology
Risk analysis (engineering)